The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision medicine means moving healthcare from a one-size-fits-all approach to a more targeted approach, where decisions are informed by each individual’s unique clinical, molecular, and lifestyle information. Working closely together with the precision medicine community, Thermo Fisher Scientific is helping advance this revolution in diagnosis and treatment. We leverage our global infrastructure and expertise to provide industry-leading capabilities, from population profiling to targeted therapeutics.
Explore our precision medicine offerings.
The Saudi Human Genome Program (SHGP) is a national project to study the genetic basis of disease in Saudi Arabia and the Middle East. This program is aimed at understanding the population’s fundamental biological makeup to help drive direct and indirect advances in medical care for decades to come by using genomic information to determine genetic risk and causality for “all health-related conditions.”
Cancer patient Nicole Gularte was on hospice with only three to five weeks to live. Test results showed that she qualified for a new CAR T-cell therapy clinical trial. Learn more about this new therapy and what it means for the future of cancer treatment.
Pharmacogenomics (PGx) envisions the widespread use of genetic testing to predict how patients may respond to particular medications, and is increasingly used during drug discovery and development. Learn about the new PGx Center of Excellence at the University of Pittsburgh, and its efforts to demonstrate the value of pre-emptive PGx testing in routine clinical care.
Since joining RUCDR, Dr. Andrew Brooks has worked to automate and develop the service infrastructure that provides high throughput sample management and analysis for DNA, RNA, and protein-based technologies to hundreds of labs globally.
Dr. Tim Triche, the co-director of the Center of Personalized Medicine at Children’s Hospital LA, believes that our understanding of cancer is still largely one-dimensional.
Read Interview ›
Dr. Mark Bouzyk, the co-founder and Chief
Scientific Officer of AKESOgen talks about his
work in precision medicine research.
Read Interview ›